UCB Pharma and HOPOS join the Rare Disease Action Forum

    10 Jan, 2022

    We are proud to welcome UCB Pharma and HOPOS as the newest members of the Rare Disease Action Forum. Reinforcing RDAF’s multi-stakeholder approach, they will be joining our other members including industry, patient organizations, healthcare professionals, and research organizations. We look forward to their contribution to the collaborative efforts at the RDAF multi-stakeholder platform. Together we will continue our efforts to improve access to diagnosis, treatment and care for patients with rare diseases in Switzerland.

    Continue reading

    The RDAF publishes its newsletter

    The newsletter, which is published twice a year, gives an overview of all the Rare Disease Action Forum (RDAF) activities during the past half year to raise awareness about rare diseases in Switzerland and improve patient’s access to diagnosis, treatment and care....

    RDAF 2022 General Assembly Meeting

    On 21 March 2022, the Rare Disease Action Forum (RDAF) held its annual General Assembly meeting. An overview of the RDAF’s activities in 2021 and an outlook for 2022 were presented. The RDAF President welcomed the new members and underlined that the collaborative...